Convergence Partners was formed in 2018 by experienced venture capital - and operational experts with a vision to establish a venture capital firm that actively supports the internationalisation and market access of European technology innovators to the 4 largest healthcare markets: US, China, India and Germany. Whereas our current investment focus is on EU HealthTech startups, Convergence is able to open its cross-border acceleration platform to any DeepTech company that is keen to accelerate growth through rapid internationalisation.
Please get in touch with us to discuss your growth and investment plans.
KEY INVESTMENT SELECTION CRITERIA
We are interested to hear from innovative EU HealthTech companies that have commercialised their technologies and are looking to accelerate scale-up.
Key Investment Selection Criteria
- B2B-focused HealthTech company with strong
international growth potential and ambitions
- Highly scalable, IP-driven business model
- Commercialised product with first revenues
Typical Deal Structure
- Significant equity minority stake
- Ticket size up to EUR 5M initially - additional capital
reserved for follow-on investments
- Board representation to support management
teams as an active sparring partner
The Convergence Team is represented in Switzerland, Germany and Spain and has additional partner hubs in Asia and the US to effectively support the internationalization of our portfolio companies. The investment team is supported by experienced venture-and operating partners, a top-class advisory board and experienced local landing & scale-up partners.